The global oncology devices market size is calculated at US$ 177.17 billion in 2026, grew to US$ 208.78 billion in 2026, and is projected to reach around US$ 914.79 billion by 2035. The market is expanding at a CAGR of 17.84% between 2026 and 2035.
The U.S. Food and Drug Administration (FDA) approved several medical devices, which are products from the newest medical technologies and are approved for specialized medical uses. The oncology devices market is experiencing massive growth due to the significant efforts of certain organizations. These include the Oncology Center of Excellence (OCE), which supports clinical projects in oncology to improve the development of oncology products for the benefit of people with cancer. The OCE introduced the Project Catalyst initiative, which has resulted in the expansion of educational resources across small pharmaceutical companies and academic life science centers to support informed anticancer therapy development.
The major surge in oncology equipment is driven by surgical and imaging devices, diagnostics and laboratory tests, radiation, nuclear medicine, and targeted therapy delivery. The oncology devices market comprises medical devices, instruments, systems, consumables, and software used for the detection, diagnosis, image-guided intervention, local tumour ablation, radiation treatment, surgical resection, and post-treatment management of cancer. It includes diagnostic imaging and biopsy tools, pathology, and molecular-diagnostic platforms where device-driven, image-guided interventional oncology (catheters, ablation systems, embolization), surgical systems and robots, radiation-therapy platforms (external beam, brachytherapy, planning & delivery software), and disposables/consumables and support services used across hospitals, cancer centres, and outpatient specialty clinics.
In October 2024, UK Research and Innovation announced £118 million funding through which new medical technologies like AI models and scanners will be trialled in the UK to diagnose cancer.
Shift Toward Minimally Invasive Technologies
Hospitals are increasingly adopting devices that reduce recovery time and improve patient comfort. Image-guided systems, robotic-assisted procedures, and precision radiation equipment are gaining attention. Future demand should focus on safer treatments, better outcomes, and technologies supporting personalized cancer care.
Growth in Early Cancer Detection
Screening and diagnostic devices are becoming more important as healthcare systems emphasize early diagnosis. Advanced imaging, molecular testing and portable technologies are expanding access. Future opportunities are expected in faster diagnostics, higher accuracy and wider use across community healthcare settings.
Rising Demand for Advanced Radiotherapy Systems
Cancer centers are investing in precise radiation technologies that target tumors while protecting healthy tissue. Proton therapy, adaptive radiotherapy and integrated treatment platforms are attracting interest. Future growth should be supported by infrastructure development and expanding oncology services worldwide.
AI/ML tools allow early detection of cancer, computer-aided detection, diagnosis, triage, and assessment. AI helps clinicians and researchers with diagnostic precision, prioritizing critical cases, and guiding treatment decisions. MRIs and CT scans are advances in AI-assisted imaging and analysis of imaging, which strongly impact the early detection of cancer.
| Sr. No. | Strategic framework | Success Rate |
| 1 | R&D | 12% of net sales in R&D investments |
| 2 | Sourcing & Manufacturing | 45% of suppliers are targeted to engage in emission reduction efforts for climate action. |
| 3 | Aftermarket & Service | 43% of net sales in services. |
| 4 | Marketing & Sales | More than 120 countries with an installed base. |
| Table | Scope |
| Market Size in 2026 | USD 177.17 Billion |
| Projected Market Size in 2035 | USD 776.3 Billion |
| CAGR (2026 - 2035) | 17.84% |
| Leading Region | North America by 40% |
| Historical Data | 2020 - 2023 |
| Base Year | 2025 |
| Forecast Period | 2026 - 2035 |
| Measurable Values | USD Millions/Units/Volume |
| Market Segmentation | By Device & Product Type, By Clinical Application/Indication, By Procedure Type/Care Pathway, By End-User/Buyer, By Region |
| Top Key Players | Varian, Elekta, Accuray, ViewRay, Siemens Healthineers, GE Healthcare, Philips, Canon Medical Systems, Intuitive Surgical, Medtronic, Boston Scientific, Johnson & Johnson, Hologic, AngioDynamics, Terumo, Cook Medical, Merit Medical, Becton Dickinson, Stryker, Olympus |
How does the Radiation Therapy Systems Segment Dominate the Oncology Devices Market in 2025?
The radiation therapy systems segment dominated the market with a revenue of approximately 28% in 2025, owing to their crucial role in oncology, from initial treatment planning, precise delivery of radiation, and detailed quality assurance. Quality assurance systems are critical parts of radiation therapy, which help in systematic protocols, audits, peer review, and verification. These systems help in targeting the tumor while reducing damage to surrounding healthy tissues.
The diagnostic imaging systems segment is expected to grow at the fastest CAGR in the market during the forecast period due to the efficient role of these systems in screening, early detection, diagnosis, and treatment planning. They help in guiding treatments, monitoring treatment response, and detecting recurrence of cancer. These emerging technologies have wide applications in molecular imaging, which enable doctors to understand tumor biology at a molecular level and allow for more personalized therapies.
| Segment | Share 2025 (%) |
| Solid Tumor External Radiation | 40% |
| Interventional Oncology | 20% |
| Surgical Oncology | 10% |
| Diagnostic & Staging Imaging | 10% |
| Brachytherapy | 5% |
| Diagnostic Biopsy & Pathology Workflows | 15% |
What made Solid Tumor External Radiation the Dominant Segment in the Oncology Devices Market in 2025?
The solid tumor external radiation segment dominated the market with a revenue of approximately 40% in 2025, owing to the assistance of these devices in treatment planning, simulation, radiation delivery, and protection of healthy tissues. The images obtained from MRI, CT scans, and PET scans are helpful to radiologists and oncologists in developing a customized treatment plan. Radiation can be performed in combination with other treatments like chemotherapy and immunotherapy to increase the effectiveness of treatments.
The interventional oncology segment is estimated to grow at the fastest rate in the market during the predicted timeframe due to the expanding role of cancer devices in guiding treatments and combination therapies. These devices and technologies include medical imaging systems, AI, robotics, and image fusion technology. The interventional oncology devices enable localized and targeted cancer treatments.
How did the Curative/Definitive External Beam Radiation Procedures Segment Dominate the Oncology Devices Market in 2025?
The curative/definitive external beam radiation procedures segment dominated the market with a revenue of approximately 35% in 2025, owing to the increased utilization of advanced oncology devices to offer high doses of radiation for treating tumors and eliminating cancer. The various oncology equipment is used in primary treatment, neoadjuvant therapy, adjuvant therapy, and combined modality therapy. There is an expansion of modern techniques for curative procedures, which include image-guided radiation therapy, intensity-modulated radiation therapy, etc.
The oncologic surgeries segment is anticipated to grow at a notable rate in the market during the upcoming period due to the huge adoption of robotic surgical systems, minimally invasive surgical tools, and ablation systems. Moreover, the increased adoption of intraoperative imaging and pre- and post-operative monitoring devices raised the need for infusion pumps and wearable technology. These devices enable surgeons to precisely diagnose, remove, and treat cancerous tissues with minimally invasive techniques.
Which Segment by End-User/Buyer Dominated the Oncology Devices Market in 2025?
The hospitals & comprehensive cancer centers segment dominated the market with a revenue of approximately 62% in 2025, owing to the critical role of CT scans, MRI scans, PET-CT scans, ultrasound, and biopsy devices in healthcare systems. They are widely applicable in radiation therapy, surgical oncology, etc. The huge adoption of robotic surgery, tumor-sensing technology, and supportive devices drives the importance of technological modernization in healthcare and cancer care.
The ambulatory surgical centers (ASCs) & outpatient oncology clinics segment is predicted to grow at a rapid rate in the market during the studied period due to the significance of image-guided surgery, minimally invasive surgical tools, biopsy systems, and robotic surgical systems. The wide utilization of chemotherapy infusion devices and external beam radiation therapy devices drives the growth of outpatient oncology clinics. There is a rapid shift towards more efficient, cost-effective, and convenient outpatient treatment.
North America dominated the market share by 40% in 2025, owing to supportive healthcare infrastructure, high healthcare spending, and favorable regulatory policies. Government programs related to oncology medical appliances in North America include research funding initiatives, changes to access and coverage policies, and pilot programs for technology review. Certain initiatives by public and private organizations aim to increase awareness about cancer prevention, screening, and treatment options, which boost the demand for diagnostic devices. The public and private funding, and R&D investments, support innovations in oncology. These significant efforts led to the development of innovative therapies and devices.
How is the Notable Growth of the U.S. in the Oncology Devices Market?
The U.S. holds a strong presence of research institutes and government organizations such as the National Cancer Institute (NCI), the Oncology Center of Excellence (OCE), Informatics Technology for Cancer Research (ITCR), and many others. They provide funding opportunities, bioengineering research grants, partnerships, and AI-based clinical decision support. Certain programs launched by the OCE include FDA-OCE programs, Oncology Specific AI initiative, Review of Diagnostic Tests, and Project Confirm, which are intended for technologies in oncology and patient care.
How does Canada Step Forward through Robust R&D in the Oncology Devices Market?
Abbott Laboratories is the leading medical device manufacturer that has expanded its presence in Canada through the launch of the first dual-chamber leadless pacemaker system, named AVEIR DR, in this country. The national research programs and robust R&D of new cancer-related technologies are supported by the government-funded bodies like the Canada Foundation for Innovation (CFI) and the Canadian Partnership Against Cancer (CPAC). The large-scale federal government programs focus on bringing oncology devices into the Canadian market.
Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period due to the rising cancer prevalence, technological advancements, and improved healthcare infrastructure. Several Asian Pacific countries implement and streamline regulatory pathways for medical devices, which boosts the review and approval process for new oncology devices. The pharmaceutical companies and medical device manufacturers in India and China are investing in R&D to accelerate innovations in oncology technologies. There is an increased demand for screening and treatment devices in the Asia Pacific due to the rising awareness of cancer prevention and treatment options among the public and patients. The public-private partnerships and government initiatives are making efforts to improve healthcare accessibility and affordability, particularly in developing economies.
China Expands Advanced Cancer Treatment
China is expanding oncology infrastructure and investing in advanced radiation therapy, surgical systems, and diagnostic equipment. Domestic manufacturers compete with global companies, often emphasizing cost and local service. NMPA regulates medical devices through registration and classification requirements. Hospitals increasingly seek image-guided treatment, proton therapy and minimally invasive technologies. Government cancer-control programs and expanding specialist centers should support demand, while localization policies continue encouraging domestic production and technology development across China.
India Broadens Oncology Device Access
India is improving cancer care capacity, with hospitals adding radiation systems, surgical devices and advanced imaging. Domestic companies compete with international manufacturers, creating options across price levels. CDSCO regulates medical devices through classification, licensing and registration requirements. Government initiatives are expanding cancer screening and treatment infrastructure through public health programs. Demand is rising for affordable technologies, compact systems and equipment suitable for regional hospitals, while private oncology networks continue upgrading treatment capabilities.
Europe is emphasizing precision treatment, better radiation control, and minimally invasive oncology procedures. Manufacturers compete through clinical evidence, safety, workflow integration and treatment accuracy. The EU Medical Device Regulation sets stricter requirements for high-risk devices, including clinical evaluation and post-market surveillance. Hospitals are investing in advanced radiotherapy, surgical navigation and imaging. Future demand should benefit from aging populations, cancer screening programs and modernization of treatment centers across major European healthcare systems.
UK Modernizes Cancer Treatment Equipment
The UK is upgrading oncology infrastructure as healthcare providers seek faster diagnosis and more precise treatment. Competition includes global device companies and specialist suppliers offering radiotherapy, surgical and imaging technologies. Medical devices follow UK regulatory requirements, while NHS procurement strongly influences purchasing. Cancer service modernization is supporting investment in radiotherapy equipment and diagnostic systems. Demand should increasingly favor technologies that improve treatment accuracy, reduce patient burden and support efficient use of clinical resources.
Germany Strengthens Precision Oncology Infrastructure
Germany remains an important market for sophisticated oncology equipment, supported by advanced hospitals and strong medical engineering capabilities. Suppliers compete on clinical performance, reliability, service, and integration with hospital workflows. High-risk devices must comply with EU MDR requirements, alongside German radiation protection rules. Cancer centers are investing in modern radiotherapy, surgical systems and imaging platforms. Aging demographics and continued healthcare modernization should sustain demand for precise, safer, and more efficient oncology technologies.
The R&D process for oncology devices encompasses key stages such as discovery and conceptualization, design and development, clinical research, regulatory review and approval, and post-market surveillance.
Key Players: Medtronic, Johnson & Johnson, GE HealthCare, and Siemens Healthineers.
Distributors play a crucial role in the management of complex supply chains that are driven by evolving healthcare needs and technological innovation.
Key Players: AmerisourceBergen, Cardinal Health, McKesson, Medtronic, Johnson & Johnson MedTech, Siemens Healthineers.
The holistic and personalized support focuses on the patient’s experience, customized care, and addresses psychosocial needs.
Key Players: Medtronic, Johnson & Johnson MedTech, Siemens Healthineers, Boston Scientific.
In February 2026, the first of its kind devices approved by the FDA for the treatment of pancreatic cancer. “Pancreatic cancer is one of the most challenging cancers to treat, and patients have long needed new therapeutic options,” said Center for Devices and Radiological Health Director Michelle Tarver, M.D., Ph.D. “This approval provides a novel, non-invasive approach that can be integrated into patients’ daily lives, expanding access to cancer care beyond traditional clinical settings.”
In August 2026, the U.S. Food and Drug Administration approved a Humanitarian Device Exemption for the OncoSil implant. It treats adults over 21 with unresectable, non-metastatic distal cholangiocarcinoma alongside chemotherapy. This makes OncoSil the first Class III medical device approved for this rare bile duct cancer.
By Device & Product Type
By Clinical Application/Indication
By Procedure Type/Care Pathway
By End-User/Buyer
By Region
Principal Consultant
Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.
Learn more about Payal Rabde
Reviewed By
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.
Learn more about Aditi Shivarkar
